ArticleSAGE open medicine2026
Etiologic spectrum and predictors of visual acuity in non-glaucomatous optic atrophy.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To determine the prevalence and underlying causes of nonglaucomatous optic atrophy (NGOA) in a tertiary referral center in southeastern Iran and to identify predictors of current visual acuity in this population. Methods: In this descriptive cross-sectional study, patients with a confirmed diagnosis of NGOA were included. All cases had a definitive etiologic diagnosis based on clinical evaluation, paraclinical investigations, and thorough review of medical records. Patients were classified into etiologic categories including hereditary or developmental disorders; secondary or consecutive optic atrophy; traumatic optic neuropathy (TON); compressive lesions; raised intracranial pressure-related involvement; inflammatory or demyelinating disease; infiltrative processes; toxic exposure; and ischemic causes. Results: A total of 155 eyes from 155 patients with NGOA were analyzed, of whom 86 (55.5%) were male. Overall, 75 patients (48.4%) had a best-corrected visual acuity (BCVA) of ≥ 1.90 logMAR (logarithm of the minimum angle of resolution), corresponding to counting fingers vision or worse. Patients with toxic optic neuropathy demonstrated the poorest visual outcomes, with 5 of 6 cases (83.3%) having a BCVA of ≥ 1.90 logMAR. Ischemic causes were the most prevalent etiology, identified in 46 patients (29.7%), including 45 cases of non-arteritic anterior ischemic optic neuropathy (AION). TON was the second most common cause, observed in 37 patients (23.9%). In multivariate analysis, a longer duration from symptom onset was the sole independent predictor of poorer current visual acuity (β = 0.253, Conclusion: Previous non-arteritic AION was the most common cause of NGOA in this cohort, followed by TON. Toxic exposure was associated with the poorest visual acuities. Among all evaluated variables, the duration from symptom onset was the only independent predictor of current visual acuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.